Trial Profile
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Merestinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 15 Mar 2024 Status changed from active, no longer recruiting to discontinued.
- 02 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2016 Status changed from not yet recruiting to recruiting.